Fulgent Genetics Q2 2023 Earnings Report

Fulgent Genetics EPS Results

• Actual EPS: -$0.33
• Consensus EPS: -$0.59
• Beat/Miss: Beat by +$0.26
• One Year Ago EPS: N/A

Fulgent Genetics Revenue Results

• Actual Revenue: $67.85 million
• Expected Revenue: $62.68 million
• Beat/Miss: Beat by +$5.17 million
• YoY Revenue Growth: N/A

Fulgent Genetics Announcement Details

• Quarter: Q2 2023
• Date: 8/4/2023
• Time: N/A

Fulgent Genetics (NASDAQ:FLGT), together with its subsidiaries, provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, municipalities and large corporations, and patients. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in El Monte, California.